The University of Texas MD Anderson Cancer Center was awarded a $1,882,607 project grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on leveraging prostate cancer's unique lipid metabolism to induce therapeutic ferroptosis. The award, which began on March 15, 2025 and will run through March 14, 2028, supports innovative scientific studies aimed at improving health outcomes for military service members, veterans, and the broader public. This federal grant award enables MD Anderson to carry out basic, translational, and clinical research activities encompassing preclinical studies evaluating novel treatments, epidemiologic studies of risk factors, and clinical trials testing new therapies, diagnostic tests, or prevention strategies related to prostate cancer.
Generated 3/18/25, 3:36 AM